Company / Shareholders' Equity
Xeris Biopharma Holdings, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$13.7M
FY2025
5-year range
-$29.6M / $95.2M
FY2021-FY2025
Trend
+146.2%
vs FY2024
Sector context
#188 of 213
Health Care
What the data says
Xeris Biopharma Holdings, Inc.'s shareholders' equity of $14M is lower than 88% of companies in the Health Care sector (FY2025). Shareholders' Equity returned to growth in FY2025 after 3 years of decline, reaching $14M.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of -16.5%.
Improved from -$7M to $14M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -26.0%
- 5-Year CAGR
- -16.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 213This company $13.7M Sector average $2.5B
▼
-99.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -16.5%, indicating a declining trend.
- In FY2025, shareholders' equity increased 146.2% year-over-year.
- Ranks #188 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.7M | +146.2% |
| FY2024 | -$29.6M | -336.7% |
| FY2023 | -$6.8M | -120.1% |
| FY2022 | $33.8M | -64.5% |
| FY2021 | $95.2M | +182.1% |
| FY2020 | $33.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026